Repeat stool-based screening rates vary widely by health system, study finds
-
July 17
In a retrospective cohort of nearly 500,000 adults, consistent repeat stool-based screening ranged from 5% to 61% across four health systems and was tied to earlier-stage cancer at diagnosis.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, describe characteristic cyst findings on cross-sectional and endoscopic sonographic imaging, fluid analysis results, and management.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
Repeat stool-based screening rates vary widely by health system, study finds
-
by Meg Barbor
In a retrospective cohort of nearly 500,000 adults, consistent repeat stool-based screening ranged from 5% to 61% across four health systems and was tied to earlier-stage cancer at diagnosis.
GLP-1 drugs don't lower IBD relapse but appear safe, study finds
-
by Olivia Anderson
A large target trial emulation found semaglutide and tirzepatide did not reduce one-year relapse rates in patients with stable inflammatory bowel disease, though both appeared safe in those with obesity or diabetes.
One in five reach hepatitis B functional cure with finite bepirovirsen
-
by Doug Brunk
In two phase 3 trials, a 24-week course produced a functional cure in about 20% of patients and let many stop antiviral therapy, while none on placebo responded.
Higher cecal intubation rates linked to fewer post-colonoscopy cancer deaths
-
by Meg Barbor
Austrian screening data suggest a cecal intubation rate above 95% may be an appropriate quality target for screening colonoscopy.
Four-week pancreatic stent interval reduces repeat endoscopies, trial finds
-
by Doug Brunk
In a nine-center Korean randomized trial, waiting four weeks instead of two to assess prophylactic pancreatic duct stents cut endoscopic removals from 19% to 7% without raising pancreatitis risk.
